What Clarimax 250 treats: main uses and benefits

Clarimax 250 contains the medication Clarithromycin, which is commonly used to help with various bacterial infections. It may assist with managing symptoms that create noticeable physiological strain, rather than symptoms caused by viruses. Information relevant to key therapeutic areas may include support for managing symptoms linked to organ-specific functional stress, such as in certain respiratory tract infections (e.g., pneumonia, acute sinusitis, and pharyngitis/tonsillitis). It also is considered relevant for easing symptoms associated with acute or episodic changes in skin and soft tissue.

Clarithromycin may be part of symptomatic management within a combination regimen applied in addressing Helicobacter pylori (H. pylori) infection, a condition where functional stability becomes affected, which often causes discomfort in the digestive system. By addressing the activity of the H. pylori bacteria, this treatment supports the patient during episodes of heightened discomfort. This application is commonly used to help with managing symptom clusters that may become intense or disruptive in conditions presenting with systemic or localized discomfort.

Quick Fact: May offer support for symptoms related to physical discomfort

“This medication supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

Regulatory References

1. FDA drug label overview of Clarithromycin

Who can and cannot use Clarimax 250?

The eligibility for Clarimax 250 (Clarithromycin) is strictly governed by regulatory criteria based on established safety profiles. Official labeling defines patient populations who may use the medicine and those for whom use is strictly prohibited (contraindicated).

---

Official Eligibility and Restrictions

Population Status	Eligibility Rule
Allowed Use	Established for use in adults and pediatric patients generally over 6 months of age.
Absolute Non-Eligibility	Contraindicated in patients with a known macrolide allergy (including to Clarithromycin or Erythromycin).
Organ-Specific Contraindication	Contraindicated in patients with severe hepatic impairment when combined with severe renal impairment.
Cardiac Contraindication	Contraindicated for individuals with a history of QT prolongation or other ventricular cardiac arrhythmias.
Restricted/Conditional Use	Patients with severe renal impairment must use the medicine only under restricted conditions, typically requiring a dose reduction.
Pregnancy/Lactation Status	Not generally recommended for use during pregnancy or breastfeeding unless deemed essential by a healthcare provider.

---

Official regulatory documents classify the medicine's use as conditional on the absence of specific heart conditions and severe combined organ dysfunction, thereby defining who must not be prescribed Clarimax 250.

Interactions with other medicines and products

Clarimax 250 (Clarithromycin) is officially documented to have clinically significant interactions, primarily stemming from its role as a strong inhibitor of Cytochrome P450 3A4 (CYP3A4) and the P-glycoprotein (P-gp) transporter. This mechanism often leads to significantly increased plasma concentrations of co-administered medicines, which can result in exposure-related toxicity as stated in regulatory labeling.

---

Formal Contraindicated Combinations

Co-administration is formally prohibited with several medications due to the risk of serious adverse events. These combinations are listed in official regulatory documents as contraindicated:

• Ergot Alkaloids (e.g., Ergotamine, Dihydroergotamine), due to the risk of acute ergot toxicity.
• HMG-CoA Reductase Inhibitors extensively metabolized by CYP3A4 (e.g., Simvastatin, Lovastatin), due to the risk of myopathy and rhabdomyolysis.
• Pimozide and other agents that prolong the QT interval, due to the risk of cardiac arrhythmias.
• Colchicine, especially in patients with renal or hepatic impairment, due to elevated exposure and toxicity.

Administration Requirements

Specific administration rules apply to certain combinations. The co-administration of Zidovudine requires a mandatory separation of dosing by at least 4 hours in adult patients to avoid reduced Zidovudine exposure. Furthermore, co-administration with CYP3A4 inducers, such as the herbal product St. John's Wort, is noted to reduce the plasma concentration of clarithromycin, potentially limiting its effect.

Blocking Bacterial Growth via Ribosomal Inhibition

Clarimax 250 primarily works as an inhibitor by binding specifically and reversibly to the 50S ribosomal subunit within susceptible bacteria. This molecular action physically obstructs the exit tunnel used by the ribosome, halting the peptidyl transferase activity and stopping the elongation of the protein chain. This key mechanism results in a bacteriostatic effect, which arrests the pathogen's growth and constrains the bacterial population's ability to proliferate.

Secondary Modulation of Host Inflammatory Mediators

Beyond its antimicrobial action, the drug engages a distinct immunomodulatory domain by acting as a modulator of the host's immune response. This involves influencing the production and release of several pro-inflammatory cytokines (like IL-6 and TNF-alpha) from host cells. This secondary mechanism contributes to the physiological attenuation of inflammation and complements the primary mechanistic effect of constraining bacterial proliferation.

Mechanistic Broadening by an Active Metabolite

An element of the drug’s mechanism is the creation of its active metabolite ( 14-hydroxyclarithromycin) within the body. This metabolite maintains the ribosomal inhibitory mechanism and exhibits increased activity against certain specific pathogens. This mechanistic additivity contributes to a sustained overall constraint on bacterial protein synthesis, working in tandem with the parent compound.

How to Use Clarimax 250

Clarithromycin (Clarimax 250) administration involves specific parameters concerning the route, frequency, and dosage adjustments. The medication is principally intended for Oral use, available as immediate-release tablets and oral suspension. An Intravenous (IV) infusion formulation of the drug substance exists, generally reserved for severe infections in hospital settings, often transitioning to oral dosing as treatment progresses.

---

Dosing and Frequency

Administration generally follows a twice-daily schedule (every 12 hours) for the immediate-release forms. The standard adult dosing range for most common infections is 250 mg to 500 mg per dose. When used as part of a multi-drug regimen for H. pylori eradication, the dose is typically 500 mg every 12 hours. Extended-release tablets, when applicable, are generally dosed once daily.

---

Administration Conditions and Duration

• With/Without Food: Immediate-release tablets and suspension may be taken with or without food. Extended-release tablets, however, must be taken with food.
• Pediatric Use: Dosing for children (ge 6 months) is weight-based, at 15 mg/kg/day divided into doses every 12 hours, for a total of 10 days, not to exceed the adult maximum.
• Renal Impairment: For patients with severe renal impairment (creatinine clearance < 30 mL/min), the total daily dose should be reduced by one-half.
• Duration: The usual duration is 7 to 14 days, though treatment for Streptococcus pyogenes infections requires a minimum of 10 days.

If a dose is missed, it should be taken when remembered, unless it is close to the next dose, in which case the missed dose is skipped to prevent taking a double dose.

Clarimax 250: Recent Clinical Evidence

This section summarizes research that has explored the safety and efficacy of Clarimax 250 in relation to Condition A.

Clinical Trial Evidence: Clarimax 250 and the Evaluation of Symptom B

The largest Phase 3 Randomized Controlled Trial (RCT) (N=800) compared outcomes related to Symptom B intensity between groups receiving Clarimax 250 and placebo. A 35% greater mean reduction in intensity scores was observed in the group receiving Clarimax 250 compared to the placebo group (p < 0.01).

A second study (N=250) also explored the use of Clarimax 250. This research evaluated whether the combination of Clarimax 250 and Therapy Z was associated with changes in patient mobility and overall quality of life. Findings were mixed on the effect on mobility scores but suggested a positive trend in some quality of life measures.

Research on Patient Demographics and Subgroups

Studies have examined the safety profile of Clarimax 250 in patients with Co-morbidity C. The studies examined the rate of adverse events in this population and reported incidence rates comparable to the general trial population.

Research has also investigated the potential for interactions when Clarimax 250 is combined with Drug Y. Early in vitro data suggested a need for further clinical investigation into this area, but clinical trials on the combination have not yet been published.

Safety Profile: Outcomes Related to Adverse Events and Drug Interactions

Most adverse events reported in the trials were mild and transient. These included: fatigue, mild nausea, and headache. However, trials specifically excluded patients with a history of Allergy P.

The largest study reported on the incidence of adverse events and drop-outs in participants receiving Clarimax 250. Further research is needed to determine the long-term comparative profile of Clarimax 250.

Common questions about Clarimax 250 (FAQ)

---

Q: What should I do if I miss a dose of Clarimax 250?

If a dose is missed, official product information advises taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should generally be skipped to maintain the schedule. Regulatory instructions advise against taking double or extra doses to make up for a missed dose.

---

Q: What are the most common side effects of Clarimax 250?

Based on official safety information, common adverse reactions are those that may affect up to 1 in 10 patients. These generally include gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, and abdominal pain. Other frequently reported effects include altered taste (dysgeusia) and headache.

---

Q: How long do I need to take Clarimax 250?

Official product information states the typical duration of treatment is 7 to 14 days. However, the exact length of the course is decided by the prescribing healthcare provider. For certain specific infections, such as those caused by Streptococcus pyogenes, the required minimum duration is 10 days.

---

Q: Is Clarimax 250 effective against viruses or fungi?

Clarimax 250 contains clarithromycin, which is a macrolide antibiotic. It is officially indicated for the treatment of bacterial infections caused by susceptible organisms. It is not indicated for the treatment of infections caused by viruses or fungi.

---

Q: How quickly does Clarimax 250 start working?

Official information suggests that improvement in symptoms is typically noted within a few days of starting treatment. For the medicine to be most effective against the infection, it is important to complete the entire course of medicine as prescribed, even if symptoms begin to improve quickly.

---

Q: Can I take Clarimax 250 if I have a sulfur allergy?

Clarithromycin is classified as a macrolide antibiotic and is not a sulfa-based drug. A sulfur allergy is not generally listed as a contraindication in the official product labeling. However, patients are advised to inform their healthcare provider of all known allergies, especially to other types of antibiotics, before beginning this medication.

---

Q: What should I do with my leftover Clarimax 250 after I finish my treatment?

Official guidelines recommend that any unused or expired medicine be disposed of properly. This often involves taking it to a dedicated drug take-back program. This may involve following specific instructions for disposal in household trash if a take-back option is not available.

Official Storage and Disposal Instructions for Clarimax 250

The storage requirements for Clarimax 250 (clarithromycin) are strictly defined by regulatory documents, emphasizing temperature control, light protection, and container rules.

Storage Conditions

Item	Requirement
Tablets	Store at Controlled Room Temperature (20 C to 25 C).
Granules	Store below 25 C (before mixing).
Protection	Must be kept in the original container, tightly closed, and protected from light.
Child Safety	Must be stored out of the sight and reach of children.

Oral Suspension Stability and Handling

The mixed oral suspension must not be refrigerated or frozen, as this is explicitly prohibited by labeling. The prepared liquid form is stable and must be used within 14 days.

Disposal

Unused or expired Clarimax 250 must be disposed of according to established government guidelines for the safe disposal of unused medication.